AUAshish Upadhyay

Ashish Upadhyay

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ashish Upadhyay has a total of 146 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Empagliflozin versus dapagliflozin for kidney outcomes in stage 3 chronic kidney disease: a propensity score-matched multi-center cohort study

    by Joyita Bharati, Nicholas A. Bosch, Ashish Upadhyay

    Sodium-glucose cotransporter 2 (SGLT2)-inhibitors are key in chronic kidney disease (CKD) management with empagliflozin and dapagliflozin being the two mos


  • Open Access

    Diabetic kidney disease, biomarkers, and finerenone

    by Ashish Verma, Ashish Upadhyay

    Diabetic kidney disease (DKD), the leading cause of kidney failure worldwide, is associated with an increased risk of cardiovascular disease (CVD). A complex pathobiology involving hemodynamic, metabolic, and immune dysregulation promotes inflammatory and fibrotic pathways that contribute to kidney disease progression and CVD in individuals with DKD. While the standard treatment approach incorporating renin‐angiotensin‐aldosterone system (RAAS) blockers and sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) reduces the risk for kidney disease progression and CVD, the high residual risk that persists despite these treatments underscores the need for novel therapies for DKD. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist (MRA), is a proven therapeutic option for DKD that targets inflammatory and fibrotic pathways involved in its progression. Furthermore, finerenone has been evaluated for DKD outcomes in phase 3 clinical trials, has a favourable side effect profile compared to steroidal MRAs, reduces the risks of major kidney and CVD outcomes in clinical trials when used with RAAS blockers, and is the only MRA specifically approved for DKD and recommended for DKD in treatment guidelines. The integration of novel biomarkers of CKD and CVD into the clinical management of DKD may improve early identification of at‐risk individuals and allow for patient‐specific therapeutic strategies. This review provides a brief overview of the pathogenesis of DKD and the role of mineralocorticoid receptor activation in DKD pathobiology, summarises the role of finerenone in the treatment paradigm of DKD, evaluates current and emerging biomarkers of DKD and finerenone's impact on these biomarkers, and provides forward‐looking guidance on future research for biomarker‐driven precision medicine in DKD.


  • A Young Man With an Unusual Pulmonary-Renal Syndrome: A Quiz

    by Joyita Bharati, Michael Carmen Baldino, Ashish Upadhyay


  • Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease: Clinical Evidence and Potential Adverse Events

    by Ashish Upadhyay, Lalarukh Haider

    Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease (CKD) globally and is associated with an increased risk of developing cardiovascular disease (CVD). DKD management requires a multipronged approach to decrease the progression of CKD and CVD. Mineralocorticoid receptor antagonists (MRAs) added to renin-angiotensin-aldosterone system blockade and sodium–glucose cotransporter 2 inhibitor therapy reduce the incidence of cardiovascular outcomes and progression of CKD. This review examines the cardiorenal benefits of MRAs and summarizes evidence on potential risks for acute kidney injury, hyperkalemia, and sexual dysfunction for steroidal and nonsteroidal MRAs.


  • Top Cited Papers
    Open Access

    SGLT2 Inhibitors and Kidney Protection: Mechanisms Beyond Tubuloglomerular Feedback

    by Ashish Upadhyay

    Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk for kidney failure and are a key component of guideline-directed therapy for CKD. While SGLT2 inhibitors’ ability to activate tubuloglomerular feedback and reduce hyperfiltration-mediated kidney injury is considered to be the central mechanism for kidney protection, recent data from experimental studies raise questions on the primacy of this mechanism. This review examines SGLT2 inhibitors’ role in tubuloglomerular feedback and summarizes emerging evidence on following of SGLT2 inhibitors’ other putative mechanisms for kidney protection: optimization of kidney's energy substrate utilization and delivery, regulation of autophagy and maintenance of cellular homeostasis, attenuation of sympathetic hyperactivity, and improvement in vascular health and microvascular function. It is imperative to examine the effect of SGLT2 inhibition on these different physiologic processes to help our understanding of mechanisms underpinning kidney protection with this important class of drugs.


  • Open Access

    End-stage kidney disease and COVID-19 in an urban safety-net hospital in Boston, Massachusetts

    by Mohamed Hassan Kamel, Hassan Mahmoud, Aileen Zhen, Jing Liu, Catherine G. Bielick, Anahita Mostaghim, Nina Lin, Vipul Chitalia, Titilayo Ilori, Sushrut S. Waikar, et al.

    End-stage kidney disease (ESKD) patients are at a high risk for Coronavirus Disease 2019 (COVID-19). In this study, we compared characteristics and outcomes of ESKD and non-ESKD patients admitted with COVID-19 to a large safety-net hospital. We evaluated 759 adults (45 with ESKD) hospitalized with COVID-19 in Spring of 2020. We examined clinical characteristics, laboratory measures and clinical outcomes. Logistic regression analyses were performed to investigate the associations between ESKD status and outcomes. 73% of ESKD and 47% of non-ESKD patients identified as Black (p = 0.002). ESKD patients were older and had higher rates of comorbidities. Admission ferritin was approximately 6-fold higher in ESKD patients. During hospitalization, the rise in white blood cell count, lactate dehydrogenase, ferritin and C-reactive protein, and the decrease in platelet count and serum albumin were all significantly greater in ESKD patients. The in-hospital mortality was higher for ESKD [18% vs. 10%; multivariable adjusted odds ratio 1.5 (95% CI, 0.48–4.70)], but this did not reach statistical significance. Among hospitalized COVID-19 patients, ESKD patients had more co-morbidities and more robust inflammatory response than non-ESKD patients. The odds ratio point estimate for death was higher in ESKD patients, but the difference did not reach statistical significance.


  • Crop Productivity Enhancement under Soybean Based Cropping System through Harvested Rain Water in Malwa Region

    by D.H. Ranade, M.L. Jadav, Indu Swarup, O.P. Girothia, D.V. Bhagat, Ashish Upadhyay

    Background: Rainwater harvesting is commonly practiced in areas, where the rainfall is insufficient for crop growing. Due to the intermittent nature of run-off events, it is necessary to store the maximum possible amount of rainwater during the rainy season so that it may be used as irrigation to enhance the crop productivity and farm income under soybean based cropping system. Methods: A study was carried out during 2018-2019 in Indore district of Malwa region. Rainwater harvesting tanks at on station (42×21×2.4m) and on farm (15×11×4m) were constructed for irrigation water availability. Provision of water harvesting tank increased the irrigation water availability (1781m3 and 630m3 respectively) and stored water was managed through various irrigation systems viz. rain gun, drip and flood. Result: It was resulted that the provision of water harvesting tanks enhanced the crop productivity and farm income under soybean based cropping system. Availability of irrigation encouraged the farmers to diversify the cropping pattern (soybean-chickpea, soybean -wheat). It is also clear from the study that even with smaller storage tank and through conjunctive use of ground (1164.2m3) and surface water (596m3), multiple crops (Soybean, potato, sweet corn, chickpea, onion, garlic etc.) can be grown. Soybean-Chickpea cropping system at station gave the net return of 70976 Rs/ha with B: C ratio of 3.15. Soybean-Wheat cropping system at farm gave the net return of 119000 Rs/ha with B:C ratio of 3.38.


  • Top Cited Papers

    Diabetic Kidney Disease

    by Ryan Bonner, Oltjon Albajrami, James Hudspeth, Ashish Upadhyay


  • CREDENCE: Significant Victory for Diabetic Kidney Disease

    by Ashish Verma, Ankit B. Patel, Ashish Upadhyay, Sushrut S. Waikar


  • Open Access

    Dialyzer reuse: is it safe and worth it?

    by Ashish Upadhyay

    Dialyzer reuse involves a complicated multistep process that includes rinsing, cleaning, performance testing, and disinfection of dialyzers prior to reuse. The process requires the use of cleaning and germicidal agents that are potentially toxic, and accidental contact with these agents may expose both patients and dialysis staff to health hazards.1,7-9 There are also reports of Gram-negative bacteremia outbreaks from the break-down in infection-control systems,10-12 and even a low-level exposure to toxins and microbiological contamination may contribute to chronic inflammation. Despite these potential risks, there are no randomized-controlled trials comparing single-use and reuse practices, and the evidence from observational studies are inconsistent.6,13 There is also a concern for conflicts of interest as studies sponsored by disinfectant manufacturers tend to show single-use and reuse practices having similar health outcomes while those sponsored by dialyzer manufacturers are more prone to show reduced risk with single-use.13,14 Notwithstanding the available evidence, given the 50 years of clinical experience with dialyzer reuse, there is a general agreement that the reuse process is likely safe when there is a strict adherence to the standards set by the Association for the Advancement of Medical Instrumentation (AAMI).15